stockrow
Friday 6 November 2026
Export SSII’s income statement to Excel — free account
SS Innovations International, Inc.
SSII Healthcare Medical Devices
SS Innovations International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $42.5 million, up 105.7% from fiscal 2024.
- Revenue
- +39.4%
- EPS
- −669.2%
- Free cash flow
- −16.6%
- Total debt
- +109.7%
Quarter to June 2026, against a year earlier
2.21
0.31
+16.32%
Follow SSII
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 6 | 21 | 42 | 52 | +207.7% | 60 | 76 | 103 | +34.5% | |
| Gross margin, % | — | — | — | — | — | — | 33.57 | 12.35 | 40.93 | 46.00 | 47.65 | +12.4 pt | ||||||
| EBT | 0 | (1) | (1) | (3) | (1) | (1) | (6) | (21) | (19) | (8) | (8) | +36.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (384.11) | (355.36) | (92.74) | (19.21) | (15.58) | (19.2) pt | ||||||
| Net income | 0 | (1) | (1) | (3) | (1) | (1) | (6) | (21) | (19) | (12) | (12) | +43.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.12 | 0.22 | 0.26 | n/m | |||||
| Earnings | (0.03) | (0.05) | (0.05) | (0.16) | (0.05) | (0.05) | (0.14) | (0.14) | (0.11) | (0.06) | (0.06) | +9.6% | ||||||
| Cash flow | (0.01) | (0.02) | (0.02) | (0.02) | 0.00 | (0.01) | (0.14) | (0.11) | (0.06) | (0.10) | (0.08) | +26.9% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | (0.02) | (0.01) | +26.1% | ||||||
| Free cash flow | (0.01) | (0.02) | (0.02) | (0.02) | 0.00 | (0.01) | (0.13) | (0.11) | (0.06) | (0.12) | (0.09) | +26.8% | ||||||
| Book value | (0.02) | 0.01 | (0.01) | (0.05) | (0.04) | 0.01 | (0.06) | 0.14 | 0.08 | 0.20 | 0.27 | n/m | ||||||
| Shares, m | 19 | 20 | 21 | 22 | 23 | 28 | 41 | 145 | 171 | 190 | 195 | +29.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 178.76 | 65.28 | 25.40 | 7.26 | 67.4 | ||||||
| P/B | — | — | — | — | — | — | 1,628.93 | 53.27 | 100.17 | 28.24 | 7.12 | 452.7 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 178.67 | 65.36 | 25.46 | 7.11 | 67.4 | ||||||
| EV/FCF | — | — | — | — | — | — | (105.20) | (67.51) | (132.78) | (48.71) | (20.45) | (88.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | 0 | 0 | 0 | 0 | (6) | (15) | (10) | (19) | (16) | +64.4% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | (1) | (4) | (3) | +63.6% | ||||||
| Free cash flow | 0 | 0 | 0 | 0 | 0 | 0 | (5) | (16) | (10) | (22) | (18) | +64.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 0 | 0 | (1) | (1) | 0 | (4) | 13 | 6 | 23 | 40 | n/m | |||||
| Net debt | 0 | 0 | 0 | 0 | 0 | 0 | 2 | (1) | 2 | 2 | (8) | n/m | ||||||
| Shareholders’ equity | 0 | 0 | 0 | (1) | (1) | 0 | (2) | 20 | 13 | 38 | 53 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 0.00 | (258.71) | (293.04) | (2,436.85) | (499.42) | (397.67) | (123.04) | (103.89) | (51.83) | (20.80) | (14.89) | (20.8) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (66.01) | (78.30) | (12.64) | (11.31) | (12.6) pt | ||||||
| ROE | 0.00 | 817.09 | 1,575.55 | 526.47 | 116.41 | 407.94 | 483.05 | (241.96) | (115.45) | (46.94) | (26.06) | (46.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 6 | 6 | 10 | 10 | 10 | 5 | 239 | 378 | 483 | — | +73.1% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.02 | 0.05 | 0.09 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
SS Innovations International, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $502.8M | 1,455× | — (loss-making) | +20.60% (above 0%: growing) | −12.50% (below 0%: shrinking) | −24.45% (below 0%: shrinking) | 89.75% | 8.22% | Compare |
| NPCE NeuroPace, Inc. | $435.6M | — (loss-making) | — (loss-making) | −2.95% (below 0%: shrinking) | n/m | −78.70% (below 0%: shrinking) | 82.83% | (22.53%) | Compare |
| CERS Cerus Corporation | $430.2M | — (loss-making) | — (loss-making) | +6.28% (above 0%: growing) | n/m | +2,471.28% (above 0%: growing) | 57.12% | 0.60% | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $427.1M | 21.2× | — (loss-making) | +35.43% (above 0%: growing) | +40.00% (above 0%: growing) | −51.68% (below 0%: shrinking) | 74.62% | 13.98% | Compare |
| SI Shoulder Innovations, Inc. | $424.1M | — (loss-making) | — (loss-making) | +37.73% (above 0%: growing) | n/m | +38.63% (above 0%: growing) | 78.47% | (46.92%) | Compare |
| SENS Senseonics Holdings, Inc. | $422.5M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| MASS 908 Devices Inc. | $419.5M | — (loss-making) | — (loss-making) | +23.31% (above 0%: growing) | n/m | +150.95% (above 0%: growing) | 51.90% | (79.69%) | Compare |
| RCEL Avita Medical Inc. | $389.5M | — (loss-making) | — (loss-making) | +53.05% (above 0%: growing) | n/m | +86.66% (above 0%: growing) | 84.02% | (17.95%) | Compare |
| SSII SS Innovations International, Inc. | $380.9M | — (loss-making) | — (loss-making) | +39.39% (above 0%: growing) | n/m | −16.62% (below 0%: shrinking) | 50.94% | (16.29%) | |
| Median of peers | $425.6M | — | — | +29.37% | — | +7.09% | 76.55% | (20.24%) |